Mesa Laboratories, Inc.

NasdaqGS:MLAB Stock Report

Market Cap: US$722.7m

Mesa Laboratories Future Growth

Future criteria checks 4/6

Mesa Laboratories is forecast to grow earnings and revenue by 134.3% and 5.6% per annum respectively. EPS is expected to grow by 134.5% per annum. Return on equity is forecast to be 27.2% in 3 years.

Key information

134.3%

Earnings growth rate

134.5%

EPS growth rate

Life Sciences earnings growth17.8%
Revenue growth rate5.6%
Future return on equity27.2%
Analyst coverage

Low

Last updated21 Nov 2024

Recent future growth updates

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08
Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

Mesa Laboratories: GKE Acquisition New Crown Jewel, Still Doesn't Move The Needle

Dec 19

Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% Hiding

Nov 20
Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% Hiding

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Oct 17
We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Jul 29
A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

May 03
Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15
Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08
Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Dec 05
Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Sep 28
Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Aug 09
Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Jun 28
We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31
Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12
A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13
Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20
Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06
Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08
Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

Earnings and Revenue Growth Forecasts

NasdaqGS:MLAB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20272631443532
3/31/2026248841474
3/31/20252351030364
9/30/2024228-2463640N/A
6/30/2024224-2504145N/A
3/31/2024216-2544244N/A
12/31/202321314144N/A
9/30/2023214-13640N/A
6/30/202321923641N/A
3/31/202321912328N/A
12/31/2022222-12025N/A
9/30/2022223-42833N/A
6/30/2022200-22327N/A
3/31/202218423539N/A
12/31/202116383943N/A
9/30/202114353638N/A
6/30/202113944244N/A
3/31/202113433537N/A
12/31/2020130-23132N/A
9/30/2020128-23132N/A
6/30/2020121-22729N/A
3/31/202011822527N/A
12/31/201911052728N/A
9/30/2019105102728N/A
6/30/201910482425N/A
3/31/201910372931N/A
12/31/2018104102830N/A
9/30/2018101-22729N/A
6/30/2018990N/A30N/A
3/31/201896-3N/A26N/A
12/31/201794-4N/A17N/A
9/30/20179411N/A14N/A
6/30/20179511N/A7N/A
3/31/20179411N/A17N/A
12/31/20169412N/A14N/A
9/30/20169011N/A9N/A
6/30/20168810N/A18N/A
3/31/20168511N/A17N/A
12/31/2015789N/A15N/A
9/30/2015769N/A16N/A
6/30/20157310N/A13N/A
3/31/20157110N/A11N/A
12/31/20146811N/A9N/A
9/30/20146410N/A11N/A
6/30/2014589N/A10N/A
3/31/2014539N/A12N/A
12/31/2013508N/A12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MLAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: MLAB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MLAB is expected to become profitable in the next 3 years.

Revenue vs Market: MLAB's revenue (5.6% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: MLAB's revenue (5.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MLAB's Return on Equity is forecast to be high in 3 years time (27.2%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 00:26
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mesa Laboratories, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vijay KumarEvercore ISI
Paul KnightJanney Montgomery Scott LLC
Tycho PetersonJefferies LLC